POLARIS GROUP
11Patents
10Active
11Granted
46Portfolio score
Filing activity: Jan 15, 2004 → Mar 29, 2018 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7323167B2 | Method of treatment with modified arginine deiminase | Emerging Cross-Sectional Technologies | 10 | Expired |
| US9333268B2 | Methods of treatment with arginine deiminase | Emerging Cross-Sectional Technologies | 8 | Active |
| US9789170B2 | Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment | Emerging Cross-Sectional Technologies | 4 | Active |
| US9731028B2 | Methods of treatment with arginine deiminase | Emerging Cross-Sectional Technologies | 3 | Active |
| US7517882B2 | Protein kinase inhibitors | Human Necessities | 1 | Active |
| US10525142B2 | Methods of treatment with arginine deiminase | Emerging Cross-Sectional Technologies | 0 | Active |
| US12281339B2 | Combination cancer immunotherapies with arginine depletion agents | Chemistry; Metallurgy | 0 | Active |
| US12370242B2 | Formulations of pegylated arginine deiminase | Chemistry; Metallurgy | 0 | Active |
| US12344645B2 | Protein conjugates | Chemistry; Metallurgy | 0 | Active |
| US7785579B2 | Modified tumor necrosis factor | Emerging Cross-Sectional Technologies | 0 | Active |
| US11235037B2 | Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies for cancer treatment | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.